Motric Bio is an Aditum Bio portfolio company founded in November 2021 following the in-licensing of our lead product candidate, MTR-601, a selective myosin-2 inhibitor of fast skeletal muscle. We successfully completed a Phase 1 study that demonstrated that MTR-601 was safe and well-tolerated. We are rapidly advancing this novel therapy, with a Phase 2 study in cervical dystonia planned to start in the first quarter of 2025.